TNFRSF17 and plasma cell myeloma: B-cell maturation antigen (BCMA)-targeted CAR-T therapy has shown remarkable efficacy and safety in patients with chemotherapy-refractory or relapsed multiple myeloma (r/r MM) in several clinical trials, with overall response rates of 50–98% and a complete response rate of 80% (1–3).